LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4659 | 4513 | 1.0323 | 1.0444 |
| BT-20 | NVP-AEW541 | 3.33 | uM | LJP5 | 72 | hr | 1097 | 3891 | 3769 | 1.0323 | 1.0456 |
| SK-BR-3 | PHA-665752 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4358 | 4223 | 1.0321 | 1.0481 |
| MCF 10A | XMD11-85h | 0.04 | uM | LJP6 | 72 | hr | 962 | 10945 | 10605 | 1.0321 | 1.0353 |
| MCF7 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4224 | 4093 | 1.0321 | 1.0455 |
| MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4658 | 4513 | 1.0321 | 1.0442 |
| MCF 10A | XMD11-85h | 0.12 | uM | LJP6 | 72 | hr | 962 | 10944 | 10605 | 1.0320 | 1.0351 |
| SK-BR-3 | PD184352 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4357 | 4223 | 1.0319 | 1.0477 |
| Hs 578T | YM 201636 | 0.04 | uM | LJP5 | 72 | hr | 658 | 3968 | 3846 | 1.0319 | 1.0384 |
| Hs 578T | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 658 | 3967 | 3846 | 1.0315 | 1.0380 |
| Hs 578T | PHA-665752 | 0.37 | uM | LJP5 | 72 | hr | 658 | 3966 | 3846 | 1.0313 | 1.0378 |
| Hs 578T | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 658 | 3965 | 3846 | 1.0311 | 1.0375 |
| MCF7 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 4219 | 4093 | 1.0309 | 1.0439 |
| MDA-MB-231 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 4652 | 4513 | 1.0308 | 1.0424 |
| MCF 10A | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 962 | 10930 | 10605 | 1.0307 | 1.0338 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4352 | 4223 | 1.0306 | 1.0458 |
| SK-BR-3 | PLX-4720 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4352 | 4223 | 1.0305 | 1.0457 |
| MCF 10A | A443654 | 0.04 | uM | LJP6 | 72 | hr | 962 | 10928 | 10605 | 1.0305 | 1.0336 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4351 | 4223 | 1.0304 | 1.0456 |
| Hs 578T | Nilotinib | 1.11 | uM | LJP5 | 72 | hr | 658 | 3961 | 3846 | 1.0300 | 1.0361 |
| BT-20 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3882 | 3769 | 1.0300 | 1.0423 |
| MDA-MB-231 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4648 | 4513 | 1.0299 | 1.0412 |
| MDA-MB-231 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4648 | 4513 | 1.0298 | 1.0410 |
| MCF7 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1209 | 4214 | 4093 | 1.0296 | 1.0421 |
| MDA-MB-231 | PHA-665752 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4645 | 4513 | 1.0291 | 1.0401 |